T. Rowe Price Investment Management, Inc. Denali Therapeutics Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $163 Billion
- Q1 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 498,969 shares of DNLI stock, worth $10.5 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
498,969
Previous 498,969
-0.0%
Holding current value
$10.5 Million
Previous $10.7 Million
4.38%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding DNLI
# of Institutions
217Shares Held
115MCall Options Held
142KPut Options Held
90.3K-
Baillie Gifford & CO14MShares$297 Million0.23% of portfolio
-
Black Rock Inc. New York, NY12.2MShares$258 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11MShares$232 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA8.27MShares$175 Million0.03% of portfolio
-
State Street Corp Boston, MA6.32MShares$134 Million0.01% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $2.84B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...